Canada Crypto Week is back. Now in its sixth year, the week-long Web3 takeover of Toronto will run July 20–26, 2026, drawing builders, investors, founders, and community members from around the world for one of the most concentrated gatherings of Web3 activity on the global calendar.

At the center of Canada Crypto Week is Blockchain Futurist Conference, taking place July 21–22 at Rebel Entertainment Complex and Cabana Pool Bar, Canada’s largest and longest-running Web3 and AI conference.

Many of the week’s events, activations, and networking experiences will take place within the festival-style conference, while the surrounding days will feature independently organized and community-driven events across the city. All events are listed and accessible through the Canada Crypto Week calendar at canadacryptoweek.com.

This year’s side event lineup is already taking shape, with a broad mix of experiences happening on-site at Rebel and across the city. Confirmed side events and activations include:

• VIP Rum Bar by Cayman Finance
• Blast Wheels IRL Racing Tournament
• Institutional Breakfast presented by SheFi
• Solana & Superteam Canada Mixer
• ETHWomen & ETHToronto
• AI Futurist Conference (across both conference days)
• Crypto & Web3 Bootcamp for Beginners
• Founder & Funder Lounge by InclusifAI
• InvestHK Workshop – Hong Kong: the Global Hub for Digital Assets
• Book Signings with Amanda Wick, Audrey Nesbitt, and Annelise Osborne
• Pudgy Penguins Canada @ Blockchain Futurist Conference
• Agentic Day @ Blockchain Futurist Conference
• CryptoMonday Toronto
• Agentic Commerce Workshop by Agnic.AI
• The Cayman-Canada Summit

Events range from free community socials to invite-only investor gatherings, beginner-friendly educational bootcamps to high-level institutional workshops. Canada Crypto Week has become the connective tissue between Futurist’s main conference and the broader Toronto Web3 community, creating a full week of programming that extends well beyond the two days on the main stage.

Organizations interested in hosting a side event during Canada Crypto Week can register through canadacryptoweek.com.

Sponsorship opportunities are also available through futuristconference.com/sponsorship-form.

Conference Tickets: futuristconference.com/toronto/ticket

For media passes or media inquiries, please contact james@futuristconference.com.

• The transaction brings the technology that already powers key components of Beeline mortgage platform fully in-house and is intended to accelerate AI deployment across mortgage origination, title operations, and future digital real estate products.
• Beeline continues to position itself as a technology-focused mortgage platform, serving both traditional homebuyers and real estate investors through digital lending tools.
• Beeline’s AI-powered customer assistant Bob has already demonstrated measurable business results, contributing to an 8% increase in lead-to-lock mortgage conversions when customers engage with the platform.
• The MagicBlocks acquisition gives Beeline greater control over AI development, while MagicBlocks will continue licensing its technology to third-party financial institutions.

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, has completed the acquisition of artificial intelligence company MagicBlocks, bringing the technology that already powers key components of its mortgage platform fully in-house.

The transaction gives Beeline complete ownership of the AI infrastructure behind Bob, the company’s proprietary artificial intelligence assistant, while providing greater control over future development across its mortgage origination and title businesses (https://ibn.fm/yG3Qc). According to Beeline, the acquisition is expected to accelerate deployment of artificial intelligence throughout its lending platform, enabling additional workflow automation, improved operational efficiency and expanded decision-support tools across multiple business functions.

MagicBlocks provides the technology behind Bob, the company’s AI-powered customer assistant, which communicates with borrowers through the website, text messaging and the digital loan application process. Management said Bob has produced measurable operating results, contributing to an 8% increase in lead-to-lock conversion rates when borrowers actively engage with the platform during the mortgage application journey. Lead-to-lock conversion is a closely watched performance metric in mortgage lending because it measures how many prospective borrowers ultimately move forward to lock a loan before closing.

Chief Executive Officer Nick Liuzza said full ownership will allow the company to expand AI capabilities more rapidly without depending on an outside technology provider. “MagicBlocks’ technology is already working inside our platform,” Liuzza said in announcing the transaction. “Full ownership gives us the ability to move faster, integrate deeper, and build on what’s already working without constraint,” Liuzza said. “Beeline was designed from the start to be a technology-first mortgage company. This acquisition is consistent with that vision and gives us greater control over how we develop and deploy AI across the business going forward.”

The acquisition also reflects a broader trend occurring across financial services. Mortgage lenders increasingly are adopting artificial intelligence to automate document collection, improve customer communication, assist underwriting decisions and reduce processing times. As competition intensifies, many lenders are looking to digital platforms to lower operating costs while improving borrower experience.

Beeline’s strategy has focused on building a technology-centered lending platform rather than relying primarily on traditional mortgage origination processes. Through its subsidiary, Beeline Loans Inc., the company provides residential mortgages, title services and home equity products while emphasizing digital workflows intended to shorten closing timelines.

According to the company, its technology platform enables many loans to close within approximately 14 to 21 days, considerably faster than traditional mortgage timelines. The company has also reported a Net Promoter Score exceeding 80, significantly above typical industry averages, although future customer satisfaction levels will depend on continued operational performance as the platform evolves.

Beyond faster processing, artificial intelligence also plays an important role in borrower qualification. Beeline says its automated systems can evaluate applicants in roughly seven to eight minutes and provide borrowers with a high level of confidence regarding mortgage eligibility early in the application process. That capability may be particularly relevant for younger borrowers whose employment patterns differ from traditional full-time salaried workers.

Many members of Generation Z and the Millennial generation participate in freelance, contract or gig-economy employment, creating additional complexity during conventional mortgage underwriting. According to figures cited by the National Mortgage Professional, homeownership rates remain comparatively low among younger generations, with affordability and mortgage accessibility continuing to present challenges (https://ibn.fm/hy0Zy). 

Beeline’s lending strategy extends beyond owner-occupied housing. The company also serves borrowers purchasing residential investment properties, reflecting growing interest among younger investors seeking rental real estate as part of long-term wealth-building strategies.

Management believes digital underwriting and automated workflows may help simplify financing for both first-time homebuyers and individuals purchasing investment properties. The MagicBlocks acquisition may also support expansion into additional product categories.

Beeline said the technology will be integrated more deeply across mortgage origination, title services, home equity products and future digital real estate transactions. At the same time, MagicBlocks will continue licensing its software platform to other mortgage lenders and financial institutions, allowing the technology to maintain an external commercial presence.

From a financial standpoint, the transaction was structured as a related-party acquisition. Prior to the deal, Beeline already owned approximately 48% of MagicBlocks. To acquire the remaining ownership interest, the company issued 209,456 shares of common stock valued at $2.25 per share, representing total consideration of approximately $471,000. According to Beeline, the transaction was supported by an independent third-party fairness opinion valuing MagicBlocks at approximately $1 million and was reviewed by a special committee of independent directors because of the existing ownership relationship.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies.
• ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate.
• The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing.
• VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches.
• The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development.

The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to support the program as it advances toward investigational new drug (“IND”) and clinical trial application (“CTA”)-enabling activities (https://ibn.fm/FNr1C). 

Although often less visible than clinical trial announcements, cell line development represents an important stage in biologic drug development. Before antibody therapies can enter human studies, developers must establish manufacturing systems capable of consistently producing sufficient quantities of highly uniform therapeutic material. Stable clonal cell lines serve as the foundation for that manufacturing process, supporting process development, analytical testing, formulation work and production of material required for nonclinical studies.

VERAXA said the resulting cell lines will be used throughout its chemistry, manufacturing and controls (“CMC”) development program as preparations continue for regulatory submissions.

The company selected ATUM because its Leap-In Transposase(R) platform is designed to support efficient production of complex multi-chain biologic molecules such as VERAXA’s BiTAC(R) T-cell engagers. According to the company, ATUM’s technology has previously supported stable cell line generation for more than 50 investigational new drug submissions, providing an established manufacturing approach for advanced antibody formats.

The announcement follows encouraging preclinical data that VERAXA presented earlier this year at the American Association for Cancer Research (“AACR”) Annual Meeting. Those studies evaluated the company’s lead BiTAC(R)-TCE candidate in laboratory and animal models, where the therapy demonstrated selective activity against cancer cells expressing both intended target antigens while sparing cells carrying only one target. The results reflected the underlying design of VERAXA’s proprietary BiTAC(R) platform.

Traditional T-cell engagers generally function by simultaneously binding a tumor-associated protein and the CD3 receptor on T-cells, directing the immune system to attack cancer cells. While the approach has demonstrated clinical benefit in certain cancers, many conventional T-cell engagers face development challenges because the targeted proteins may also be present on healthy tissue, increasing the risk of unintended immune activation and treatment-related toxicity.

VERAXA’s BiTAC(R) strategy seeks to address that limitation through a different molecular design. Instead of delivering one fully active molecule, the technology divides the therapeutic into two complementary precursor molecules. Each precursor independently recognizes a different tumor-associated target but remains incapable of activating T-cells on its own.

Only when both precursors bind simultaneously to two distinct targets on the same cancer cell is the CD3-binding function reconstructed, activating the immune response. This “AND-gated” mechanism is intended to concentrate T-cell activity on cells displaying both target markers while reducing effects on healthy tissues expressing only one antigen.

The company believes this conditional activation approach could broaden the therapeutic window by maintaining anti-cancer activity while reducing off-target toxicity. That hypothesis will require further validation through future preclinical and clinical studies.

VERAXA has also continued investing in its broader research infrastructure. In June, the company announced a more than 60% expansion of laboratory space at its research and development facility in Heidelberg, Germany (https://ibn.fm/O6eTH). The additional capacity is intended to accommodate planned research staff growth, new laboratory equipment and expanded development activities as multiple proprietary and partnered programs move toward early clinical development.

The Heidelberg location also places VERAXA within one of Europe’s established biomedical research clusters, providing proximity to academic institutions and oncology research organizations.

The company continues to build a diversified oncology pipeline that extends beyond its BiTAC(R) platform. Alongside BiTAC(R) T-cell engagers, VERAXA is developing bispecific antibody-drug conjugates (“ADCs”), additional engineered antibody formats and other oncology candidates derived from technologies originally developed through scientific discoveries at the European Molecular Biology Laboratory (“EMBL”).

For more information, visit the company’s website at www.Veraxa.com. 

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

• Earth Science Tech acquires, operates, optimizes, and manages autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development
• This approach has created a “conglomerate” business model that separates ETST from other healthcare companies and enables the company to capture the profit margins at every step that other companies are forced to outsource
• ETST’s competitive advantages include its end-to-end vertical integration that covers all aspects of patient care (consultation, pharmacies, and fulfillment) as well as the provision of B2B tech and real estate
• This vertical integration has resulted in direct revenue growth while continually building the company’s product pipeline

Earth Science Tech (OTC: ETST) has shown how its fundamental competitive advantages is able to build profit while serving its expanding base of customers more effectively. As a multifaceted and diversified holding company, ETST creates value by acquiring, operating, optimizing, and managing autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development. This strategy is baked in to the company’s “conglomerate” business model, which deviates from the traditional healthcare stock, insulating the company from sector-specific risks and shocks.

Within the healthcare domain, ETST is focused on building a vertically integrated platform that seamlessly integrates all aspects of patient care, from telemedicine (consultation) and pharmacy, through to fulfillment. With Peak Curative LLC, the company’s wholly owned subsidiary and telemedicine referral platform, ETST offers asynchronous consultations for Peak-branded compounded medications.

The Peak Curative telehealth platform enables users to discreetly explore various treatment options for things like weight loss and hair growth, connecting online users with licensed medical providers. The provider can approve necessary medication, with Peak Curative then shipping the products directly. These medications are prepared at RxCompound and Mister Meds, ETST’s wholly owned compounding pharmacies that aim to make prescription fulfillment fast and easy.

Similar efficiency is found in Miami-based RxCompound, providing bespoke medications not available from commercial manufacturers. RxCompound has developed an extensive range of affordable formulations designed to meet unique patient requirements. In addition, Texas-based Mister Meds serves as a licensed compounding pharmacy and hazardous drug handler.

RxCompound and Mister Meds are both synchronized into the company’s MOCTeledoc doctor network, creating a fully vertically integrated telehealth and pharmacy ecosystem. Accessible through MyOnlineConsultation.com, MOCTeledoc provides technology and clinical staffing solutions to digital health companies and helps clinics and third-party telemedicine platforms deliver efficient care. It represents an infrastructure-as-a-service tool that enables ETST to tap into the high-margin B2B revenue stream, powering the healthcare industry as a whole, rather than focusing solely on individual consumers (patients). Interestingly, this tool has the net effect of enabling ETST to actively profit by servicing its own competitors.

Besides empowering ETST to serve patients more effectively and generate revenue, the vertically integrated business model also helps feed the company’s product pipeline, as Giorgio R. Saumat, CEO and Chairman of the Board, explained in a BioMedWire Podcast episode (https://ibn.fm/VZSyE). “We always have research and development going on. The compounding pharmaceutical (space) is not your off-the-shelf kind of pharmaceutical products, so we’re always looking for something new. We have our doctors that are constantly suggesting new compounds for… sexual health, hair loss, or skincare. I know that right now, Peaks is working on an anxiety medication. We have a very good pulse into where the healthcare community is going when it comes to health and wellness,” said Mr. Saumat. “I think our pipeline is strong and as we continue to diversify and build on these products, we’ll see the results of that,” he added. 

The expected results Giorgio referenced in his forward-looking statement will build on the progress recorded in Earth Science Tech’s fiscal year-end 2026 results (https://ibn.fm/ZlM3k). The company’s revenue grew 8% year over year, while gross profits and net income increased 5% and 11%, respectively. According to Mr. Saumat, these results were driven “by the work we have done to better integrate the patient experience across our platform….”

ETST’s end-to-end vertical integration means that it owns the healthcare ecosystem, relies on its in-house B2B tech stack, provides a proprietary doctor network to competitors, controls the supply chain (from the manufacture of medications to shipping), and owns real estate through its Avenvi subsidiary. As a result, Earth Science Tech captures the profit margins at every step that other companies are forced to outsource.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at  https://ibn.fm/ETST

• Clinically validated, advanced surgical robotics technology platform.
• Differentiated SSi Mantra system attributes (e.g., cost advantages, cardiac and pediatric surgery capabilities, ease of use and training, and pioneering telesurgery features).
• Large and growing addressable market with favorable industry tailwinds.
• Stronghold in India, global expansion underway, and potential catalysts in the US and EU.
• World-class R&D and manufacturing facilities to support growth.
• Robust sales growth, expanding margins, and increasing mix of recurring revenue.
• Aligned, accomplished management team and Board of Directors.

SS Innovations International (NASDAQ: SSII) develops differentiated surgical robotic technologies, highlighted by its advanced, cost-efficient SSi Mantra surgical robotic system. Spearheaded by a team of visionary engineers and Dr. Sudhir Srivastava, an acclaimed robotic cardiac surgeon and the company’s founder, Chairman and Chief Executive Officer, the SSi Mantra features differentiated capabilities in areas such as telesurgery, cardiac surgery and pediatric procedures. The SSi Mantra’s broad-based surgical robotic applications, modularity, user friendliness, training capabilities, clinical track record and relative cost advantages have contributed to its early commercial success.

SS Innovations is a rapidly growing American company headquartered in India and expanding globally with an eye on democratizing access to cutting-edge surgical robotic technologies. After commencing commercial operations in late 2022, the company’s annual revenue has grown from approximately $5.9 million in 2023 to $42.5 million in 2025, corresponding to a compounded annual growth rate of 169%. Nearly 500 employees and more than 90,000 square feet of world-class R&D and manufacturing facilities support the company’s growth.

The SSi Mantra has been approved for commercial use in 14 countries, and the company currently is pursuing regulatory approval of the SSi Mantra from the U.S. Food and Drug Administration as well as a European Union CE marking.

SSi Mantra

The SSi Mantra is SS Innovations’ proprietary surgical robotic system and serves as the foundation of the company’s technology portfolio. As of May 31, 2026, the SSi Mantra global installed base totaled 210 systems. The platform features a modular architecture with three to five robotic arms, an open-faced surgeon command center, a 3D 4K visualization system and integrated imaging capabilities designed to support a wide range of minimally invasive procedures.

The system has been validated for use across numerous surgical specialties, including general surgery, urology, gynecology, colorectal, cardiac, gastrointestinal, head and neck, thoracic and breast and plastic surgery procedures. According to company disclosures, the SSi Mantra has been utilized in more than 11,700 surgeries, including hundreds of cardiac procedures, pediatric procedures and telesurgeries, and has been clinically validated across more than 170 different surgical procedure types.

SS Innovations also developed the SSi MantrAsana tele-surgeon console — a portable, compact chair-based version of the surgeon command center designed to facilitate remote surgery. The company’s SSi Mantra platform has been utilized in more than 175 telesurgeries, including complex cardiac telesurgeries and multiple long-distance international procedures. In May 2026, a robot-assisted heart procedure was successfully performed with the SSi Mantra across approximately 12,500 miles (20,000 kilometers) of fiber network distance between Guyana and India, making it the world’s longest-distance robotic telesurgery ever conducted. The SSi Mantra’s tele-surgical architecture has been specifically designed to maintain procedural precision across high-latency, long-haul network environments.

SSi Mudra

SSi Mudra is the company’s portfolio of robotic surgical instruments designed for use with the SSi Mantra platform. The product line includes more than 40 instrument types spanning monopolar and bipolar cautery instruments, clip appliers, needle drivers, graspers and specialty instruments developed for robotic cardiothoracic procedures.

The instrument portfolio supports a broad range of surgical applications and includes tools developed specifically for pediatric and cardiac surgery. SS Innovations positions SSi Mudra as an integral component of its surgical robotics ecosystem, providing procedure-specific instrumentation across multiple specialties.

SS Innovations receives recurring revenue from the sale of robotic surgical instruments. Recurring revenue represented approximately 15% of total revenue in 2025 per company disclosures.

SSi Maya

SSi Maya is a mixed-reality surgical platform developed to support visualization, training and procedural planning. The platform incorporates technologies such as 3D holographic imaging, virtual surgery tools, tele-proctoring capabilities and artificial intelligence-based anatomy segmentation.

SS Innovations designed SSi Maya to support surgeon education and procedural preparation while expanding access to advanced training resources. The platform is intended to complement the company’s robotic surgery technologies by providing immersive digital tools for surgical learning and collaboration.

A subsidiary of SS Innovations, the SS International Center for Robotics Surgery (“SSICRS”), graduated its first class in June 2026 from a specialized cardiac training program designed to provide surgeons, medical residents, anesthesiologists, and other healthcare professionals with theoretical classroom instruction and practical hands-on learning in robotic-assisted surgery. The center’s virtual and in-person instruction leverages both the SSi Mantra and SSi Maya. The company aims for SSICRS to become one of the world’s premier training institutes for robotic surgery.

Market Opportunity

According to Markets and Markets, the global surgical robotics market was valued at approximately $12.0 billion in 2024 and is projected to grow to approximately $27.1 billion by 2030, representing a compound annual growth rate of 14.7%.

According to estimates cited in the company’s investor presentation, less than 1% of surgeries performed globally are currently robotic procedures. The company believes this low level of penetration highlights a substantial opportunity for broader adoption of robotic-assisted surgery as healthcare providers seek minimally invasive treatment options and advanced surgical technologies.

The company further notes that, while approximately 95% of the world’s population resides outside the United States, Europe and Japan, only about 5% of installed surgical robotic systems are located in those regions. SS Innovations has positioned its technology portfolio to target healthcare markets that have historically experienced limited access to robotic surgery platforms.

Leadership Team

Dr. Sudhir Srivastava, Founder, Chairman and CEO, is a robotic cardiac surgeon and entrepreneur who founded SS Innovations to advance the accessibility of robotic surgery technologies. He has performed one of the largest volumes of robotic cardiac procedures globally and pioneered several robotic beating-heart TECAB procedures, including multiple world-first operations. In addition to leading SS Innovations, he has trained surgical teams around the world and has been actively involved in the development and advancement of robotic-assisted surgical techniques for decades. As of June 12, 2026, Dr. Srivastava owned approximately 108.6 million SSII shares, or 54.3% of total shares outstanding.

Dr. Frederic Moll, Vice Chairman, is a physician, entrepreneur and medical robotics pioneer widely recognized for his contributions to minimally invasive surgery. He co-founded Intuitive Surgical and helped develop the da Vinci robotic-assisted surgery system. Dr. Moll also founded Hansen Medical and Auris Health and has served on the boards of multiple healthcare technology companies focused on robotics, imaging and cancer treatment technologies. As of June 12, 2026, Dr. Moll owned approximately 20.8 million SSII shares, or 10.4% of total shares outstanding.

Dr. Vishwajyoti Srivastava, Chief Executive Officer – APAC and Board Member, has been involved in robotic surgery technologies since 2008. His work has included the development of robotic surgery training platforms, tele-mentoring initiatives and advanced medical visualization systems. He previously led development of the OMNI 3D Medical Visualization platform and currently oversees activities supporting the continued advancement and expansion of SS Innovations’ technology platform.

Barry Cohen, Chief Operating Officer – Americas and Board Member, brings decades of experience in public-company management, medical technology and capital markets. He founded Avra Medical Robotics and has held leadership positions with several public and private companies throughout his career. His background includes more than 50 years managing industrial and technology-focused businesses and extensive experience in securities and corporate operations.

For more information, visit the company’s website at https://ssinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• As the demand for AI continues to accelerate and supply falls behind, BluSky AI is positioning its SkyMod AI data center model as another solution to the extensive compute needs.
• BluSky AI’s solution targets many of the most common pain points in the AI industry, such as build-out time, size, and both energy and water requirements. 
• The company is led by a team of experts with decades of experience in technology, data centers, finance, telecommunications, energy, and other industries.

As technology continues to evolve, so does the power of artificial intelligence, and the demand for the computing infrastructure needed to support it. According to Jensen Huang, CEO of NVIDIA, AI workloads can require anywhere from 100x to 1000x more computing power than traditional computing applications. As a result, demand for AI compute has reportedly increased by as much as one million-fold over the past two years. Goldman Sachs predicts that the enterprise market will see a 24x increase in AI by 2030

BluSky AI aims to help address this growing infrastructure gap through a more sustainable and environmentally conscious approach (https://ibn.fm/rlg0N). 

Recently, BluSky AI Inc. hosted an OTC investor presentation highlighting the company’s operations, long-term vision, and its strategy to address one of the fastest-growing challenges in the technology sector: the global shortage of AI compute infrastructure.

At the center of BluSky AI’s strategy is its mission to build the next generation of AI infrastructure through a network of scalable, prefabricated AI factories designed to accelerate AI compute capacity worldwide.

The company’s broader vision is equally ambitious. BluSky AI aims to support a future where artificial intelligence drives human progress through high-performance, sustainable compute infrastructure that expands global capabilities while minimizing environmental impact.

During the presentation, BluSky AI emphasized a growing imbalance within the AI industry. Demand for AI-powered services and applications continues to surge at an unprecedented pace, while the supply of compute infrastructure struggles to keep up. As adoption accelerates across industries, many analysts expect a multi-year shortage of AI compute capacity. At the same time, the global AI market is projected to grow into a multi-trillion-dollar opportunity over the coming decades.

BluSky AI believes it is well-positioned to help address this challenge through its proprietary SkyMod design, a modular, prefabricated approach to AI data center development intended to bridge the widening gap between supply and demand.

Unlike traditional hyperscale data centers, BluSky AI’s model is built around speed, efficiency, and sustainability. The company states they are targeting deployment significantly faster, require less energy per location, and little to no water in cooling, occupy a smaller footprint, and place less strain on local infrastructure and communities. The design also incorporates distributed deployment strategies and sustainable energy solutions.

According to the presentation, BluSky’s modular AI factories could dramatically reduce development timelines compared to conventional data centers, potentially cutting deployment from several years to approximately 12 months. The company also highlighted lower power requirements, reduced water consumption through closed-loop cooling or air-cooled systems, and smaller facility footprints compared to traditional large-scale campuses.

Rather than pursuing a “bigger is better” strategy, BluSky AI is focused on rapid deployment, modular scalability, and disciplined execution. The company views this approach as better aligned with the evolving needs of the AI industry, especially with new Inference demands.

The BluSky AI team has been stating that they are focused on building a future network of AI Factories for training, but also with a core in targeting inference needs, and the 80% Training models will flip to inference. At the GTC Conference CEO Jensen Huag agree by stated, “The Inflection Point for Inference has arrived”. 

Another key component of the company’s strategy is its Neocloud platform, which is expected to leverage a portfolio of SkyMod AI Factory locations across the United States with projected future capacity exceeding 250 MW. BluSky AI believes the platform is uniquely positioned to address several key AI infrastructure bottlenecks by targeting faster time-to-market, near-term revenue opportunities, scalable client solutions, and reduced risks associated with lengthy development cycles.

The company also outlined several advantages their digital infrastructure may offer over traditional cloud infrastructure, including enhanced compute availability, improved cost efficiency, interoperability, streamlined user experiences, and greater flexibility for innovation. They reviewed their opportunity for providing GPU-as-a-Service for “start-up to scale-up” and providing bare metal solutions for dedicated AI applications, as well as providing resources to other Neoclouds. 

Beyond its technology and infrastructure strategy, BluSky AI emphasized the depth of experience within its leadership team, which spans finance, data centers, telecommunications, technology, blockchain, natural resource development, and energy.

The company is led by CEO Trent D’Ambrosio, whose background includes natural resource development, hedge fund management, hyperscale data center development, and telecommunications, including involvement in the first transatlantic fiber cable project and the development of a successful mining company.

BluSky AI’s executive team also includes CTO Julien Bedard, who is known for launching an early Bitcoin escrow and anti-fraud platform, and COO Dan Gay, who brings Fortune 500 leadership and business expansion experience, Riley Cooney who was a Core Scientific Director in the early days expanding from 8 MW to over 800 MW and assisting in their IPO, and Andi Huels who is their Chief AI Officer who held that same capacity at Lenovo Computers. 

For more information, visit the company’s website at BluSkyAIDataCenters.com.

NOTE TO INVESTORS: The latest news and updates relating to BSAI are available in the company’s newsroom at https://ibn.fm/BSAI

• Forward Industries manages a Solana treasury platform, targeting active participation in the Solana ecosystem in a variety of ways, such as staking and lending.
• Currently, Forward Industries’ SOL treasury has liquid SOL holdings of over 7 million, and its validator infrastructure has generated yields that outperforms other peer validators.
• The company also recently made an offer and publicized a letter of intent (“LOI”) to acquire the Solana Company.

Forward Industries (NASDAQ: FWDI) is a Solana treasury company that’s backed by some of the most influential investors in the digital asset space. It aims to create long-term shareholder value by actively participating in the Solana ecosystem through various on-chain activities like staking, lending, and decentralized finance (“DeFi”).

It also became the first U.S.-listed company to bring its common stock to the Solana blockchain, highlighting Forward’s focus on digital-native capital markets. 

The company also recently announced a letter of intent and made an offer to acquire the Solana Company. It believes that partnering with the Solana Company would be great for both companies, and that the combined scale, Solana expertise, and efforts will allow both companies to realize and sustain the value embedded in the organizations.

Since the inception of Forward’s SOL treasury strategy, it has amassed liquid SOL holdings of more than 7 million, and Forward’s validator infrastructure has generated between 6.5% and 7.2% gross annual percentage yield (“APY”) before fees, outperforming many other top peer validators. In addition, approximately 25% of Forward’s SOL holdings are represented as fwdSOL, which is its proprietary liquid staking token that lets it earn native staking yield while still maintaining liquidity. 

Forward has enjoyed a great 2026 thus far, and some highlights include strong revenue growth, a strategic share repurchase, and strong cash reserves of around $16 million. It also recently added Mark Brazier, a very experience financial and digital assets executive, to the team as the new CFO.

Speaking about the team, Forward is led by a group of experts with many years of experience in finance, fintech, digital assets, the blockchain, and more.

This includes Chairman Kyle Samani, who was one of the first investors and major advocates for Solana, and Interim CEO Mike Pruitt, who has decades of capital markets and public company leadership experience.

About Forward Industries Inc. (NASDAQ: FWDI)

Forward Industries is building and managing a large-scale Solana (SOL) treasury platform, and is backed by many of the most influential investors in the digital space. It aims to create long-term shareholder value by participating in the Solana ecosystem. Specifically, it creates this value by accumulating SOL, and strategically deploying assets through various on-chain activities including lending, staking, and participating in decentralized finance (“DeFi”).

For more information, visit the Forward Industries website at www.ForwardIndustries.com.

NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://ibn.fm/FWDI

• Dr. Robert V. Duncan has been appointed an independent scientific and strategic advisor, adding critical expertise in national laboratories, research leadership, and technology commercialization.
• The company has also finalized a comprehensive testing protocol for the upcoming validation of its 5MW Pre-Production Texatron(TM) Fusion Engine(TM).
• The testing framework is designed to support independent scientific evaluation, with calibrated diagnostics, third-party observation and public reporting planned.
• American Fusion(TM) continues to expand its intellectual property portfolio, with additional patent applications covering elements of the Texatron(TM) platform, and recently presented its technology at IEEE ICOPS 2026, engaging with researchers and engineers in the plasma science community.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has taken further steps in advancing its fusion energy development program, appointing an experienced physicist as an independent scientific advisor while completing the testing framework that will govern validation of its Texatron(TM) Fusion Engine(TM) platform.

The company announced that Dr. Robert V. Duncan has joined American Fusion(TM) as an Independent Scientific and Strategic Advisor. Dr. Duncan brings more than three decades of experience spanning physics research, national laboratories, university leadership and technology commercialization. He currently serves as President’s Distinguished Chair in Physics and Professor of Physics at Texas Tech University (https://ibn.fm/DSSTi).

During his career, he has also held senior positions including Vice President for Research at Texas Tech University, Vice Chancellor for Research at the University of Missouri, Distinguished Member of Technical Staff at Sandia National Laboratories and Founding Director of the New Mexico Consortium at Los Alamos National Laboratory.

His experience extends beyond academic research. Dr. Duncan has served on the United States Air Force Scientific Advisory Board, participated on National Academy of Sciences panels and worked as a NASA Flight Principal Investigator. He is also a Fellow of both the American Physical Society and the National Academy of Inventors.

According to American Fusion(TM), his scientific background covers areas including superconductivity, cryogenic instrumentation, advanced materials, isotope physics, scientific diagnostics and fusion-related energy systems. Equally relevant from an investor perspective is his record in intellectual property development and technology commercialization. Dr. Duncan is named on numerous U.S. and international patent filings, several of which have supported commercial technology ventures.

Chief Technology Officer Dr. John Brandenburg said Dr. Duncan’s experience across government laboratories, advanced energy research, instrumentation and intellectual property development will provide independent scientific perspective as the company advances the Texatron(TM) Fusion Engine(TM) platform. Executive Chairman Brent Nelson added that the appointment reflects the company’s effort to strengthen its scientific and governance framework as development progresses.

The advisory appointment coincides with another milestone announced by the company. American Fusion(TM) said it has completed the comprehensive testing protocol that will guide validation of its 5MW Pre-Production Texatron(TM) Fusion Engine(TM), establishing a structured engineering framework intended to evaluate system performance, operating characteristics and safety (https://ibn.fm/lclTq).

Rather than relying on a single performance metric, the testing program incorporates multiple scientific measurements designed to characterize different aspects of plasma behavior and system operation.

Among the planned evaluations are plasma density measurements, plasma temperature monitoring, neutron detection, optical spectroscopy and detailed electrical power analysis. Together, these diagnostics are intended to generate engineering data describing plasma confinement, fusion conditions and overall system performance.

The company also said all diagnostic equipment will undergo documented calibration procedures before testing begins, with recognized standards used where applicable to improve data quality and repeatability.

Another element of the testing framework involves independent observation. American Fusion(TM) intends to invite qualified scientists, engineers and physicists to observe portions of the testing program and review engineering results. The company has also stated that future testing activities are expected to include publicly released video documentation together with independent third-party reports evaluating the results.

Fusion remains an emerging technology sector where many companies are pursuing different approaches to plasma confinement, fuel cycles and reactor design. American Fusion(TM) is developing an aneutronic fusion platform through its wholly owned subsidiary, Kepler Fusion Technologies. Unlike conventional fusion concepts that generate significant neutron flux, aneutronic approaches are intended to minimize neutron production, although neutron monitoring remains part of the company’s testing program to characterize operating conditions.

Alongside engineering development, the company continues expanding its intellectual property portfolio. Its most recent patent filing covers aspects of the Texatron(TM) Fusion Engine(TM) architecture, including a toroidal chamber design featuring a rifled interior geometry intended to receive pulsed electrical energy. Management said the filing forms part of a broader patent strategy spanning plasma confinement, diagnostics, power delivery, manufacturing methods and related technologies.

American Fusion(TM) also reported continued engagement with the scientific community following Dr. Brandenburg’s presentation at the IEEE International Conference on Plasma Science (“ICOPS”) 2026. Company representatives said discussions with researchers, engineers and physicists attending the conference provided technical feedback as development of the Texatron(TM) platform continues.

American Fusion(TM) is pursuing a modular approach through the Texatron(TM) Fusion Engine(TM), targeting future applications across industrial facilities, commercial infrastructure, defense systems and grid-constrained environments.

The company emphasized that current activities remain focused on engineering validation and commercial deployment. With its testing framework now established and scientific advisory capabilities strengthened, management said the next phase includes installation of the 5MW pre-production system, integration of diagnostic instrumentation, continued regulatory coordination and execution of the planned validation program.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration.
• Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows.
• With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions.

What begins as a localized cartilage defect can ultimately evolve into a significant clinical and economic challenge. Unlike many tissues in the body, articular cartilage has little ability to regenerate on its own, leaving untreated lesions vulnerable to progressive deterioration that may culminate in osteoarthritis (“OA”).

Historically, healthcare providers have had limited options for addressing cartilage damage before it progresses to more severe joint deterioration. Conventional microfracture procedures are relatively simple and cost-effective but often produce fibrocartilage with limited long-term durability. Meanwhile, cell-based regenerative therapies can involve multiple surgeries, extensive laboratory processing and substantial treatment costs, creating major barriers to widespread adoption.

Today, advances in regenerative medicine are creating new opportunities to address cartilage damage more effectively and efficiently. Among them is Regentis Biomaterials Ltd. (NYSE American: RGNT) Gelrin C, a cell-free, 10-minute procedure of an off-the-shelf hydrogel designed to support cartilage regeneration while avoiding many of the logistical and economic challenges associated with complex multi-stage procedures.

The commercial thesis behind GelrinC is that cartilage repair does not only need better biology. It needs a product architecture that can be adopted. Hospitals need procedures that fit existing operating room workflows. Surgeons need techniques that are practical to learn and repeat. Payers need solutions that do not carry the logistical and financial burden of individualized cell therapy. GelrinC’s off-the-shelf, cell-free, single-stage design directly addresses those adoption barriers.

The Economic Drain of “Wait and See”

When a cartilage defect is ignored or poorly treated, the financial toll quickly multiplies:

The economic consequences of untreated cartilage damage extend far beyond the initial injury. As cartilage defects progress toward osteoarthritis (“OA”), healthcare costs can rise dramatically through ongoing physician visits, imaging, injections, rehabilitation programs and, in many cases, eventual joint replacement procedures. Studies suggest that the lifetime cost of managing a patient who develops knee OA can exceed $140,000, while a large U.S. claims-based analysis estimated that newly diagnosed knee OA patients incur healthcare costs nearly double those of matched controls. Based on prevalence and treatment utilization data, researchers estimated the annual economic burden of knee OA in the United States at approximately $5.7 billion to $15 billion in financial strain. Beyond direct medical expenses, cartilage injuries often affect younger, active individuals, creating additional costs through reduced productivity, workplace absenteeism and disability.

Disrupted Dynamics: How Gelrin C Rewrites the Financial Math

The challenge for healthcare systems has historically been the lack of an ideal middle ground between relatively inexpensive procedures and more complex regenerative approaches. Conventional microfracture techniques are widely used but often ineffective as they result in fibrocartilage that lacks the durability and biomechanical properties of native cartilage. Meanwhile, cell-based therapies can involve multiple surgical procedures, specialized laboratory processing and significantly higher upfront costs, creating barriers for providers, payers and patients alike.

Regentis Biomaterials believes Gelrin C may offer a different approach. The company’s cell-free, off-the-shelf hydrogel is administered in a 10 minute procedure which minimizes trauma while avoiding the logistical complexities associated with harvesting, expanding and reimplanting a patient’s cells. Because the treatment is delivered in a single surgical setting, it has the potential to simplify care pathways while reducing many of the costs traditionally associated with advanced cartilage repair.

The Macroeconomic Reality of a 10-minute Procedure 

The economic rationale is supported by the product’s underlying design. Gelrin C consists of a hydrogel matrix combining polyethylene glycol (“PEG”) and denatured fibrinogen. The material is applied directly to the cartilage defect and cured with ultraviolet light in approximately 90 seconds, forming a solid matrix that conforms to the defect site. Over time, the implant gradually erodes and resorbs as new tissue develops. According to Regentis, clinical studies have demonstrated the formation of hyaline-like cartilage and substantial improvements in pain and function, outcomes that could prove increasingly important as healthcare systems seek solutions capable of addressing cartilage damage before it progresses to more costly degenerative joint disease.

From a health economics standpoint, this changes everything. With an estimated 470,000 annual knee cartilage repair cases in the U.S. representing a $3 billion market, insurers have long resisted covering expensive cell-based treatments. Gelrin C eliminates this friction by offering an economic sweet spot: it scales down the cost of advanced regenerative medicine to a level that is easily absorbed by hospital budgets and insurance frameworks, fundamentally preventing the downstream progression to expensive osteoarthritis.

From a health economics perspective, the appeal of Gelrin C lies in its ability to address a significant unmet need without introducing the complexity typically associated with advanced regenerative therapies. With an estimated 470,000 cartilage repair procedures performed annually in the United States, representing a market opportunity of approximately $3 billion, healthcare providers and payers continue to seek solutions that balance clinical outcomes with economic practicality. By utilizing a cell-free, off-the-shelf approach that integrates into existing surgical workflows, Gelrin C is designed to reduce many of the logistical and cost-related challenges that have historically limited broader adoption of regenerative cartilage repair technologies.

As Regentis Biomaterials advances its commercialization efforts, the company is positioning itself within a large and underserved segment of orthopedic medicine. Gelrin C’s single-step treatment approach, proprietary hydrogel technology and growing body of clinical data differentiate it from both conventional microfracture procedures and more complex cell-based alternatives. Equally important, the technology has been designed to fit within existing healthcare infrastructure, potentially lowering barriers to physician adoption and reimbursement. If Gelrin C continues to demonstrate its ability to support durable cartilage regeneration while maintaining a practical economic profile, Regentis could be well positioned to participate in the growing demand for regenerative solutions aimed at preserving joint health and delaying the progression of osteoarthritis.

For more information, visit the company’s website at www.Regentis.co.il.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai.

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN.

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

• Updating a Mineral Resource Estimate under SEC Regulation S-K 1300 represents an important milestone for companies listed on U.S. exchanges.
• Greenland Mines is also continuing to advance the Sarfartoq Neodymium-Praseodymium Rare Earth Magnet Project on several additional fronts.
• According to the company, Sarfartoq is distinguished by its concentration of neodymium and praseodymium, commonly referred to as Nd Pr.

As governments and manufacturers race to secure reliable supplies of rare earth elements for electric vehicles, renewable energy technologies and defense systems, projects that can advance toward modern resource estimates and economic studies are drawing increasing attention. Greenland Mines (NASDAQ: GRML), a mineral exploration and development company focused on building a strategic portfolio of critical mineral assets in Greenland, recently announced a significant step forward in the development of its Sarfartoq Neodymium-Praseodymium Rare Earth Magnet Project through an accelerated program to update the project’s mineral resource estimate in accordance with U.S. Securities and Exchange Commission Regulation S-K 1300.  

The company has engaged Tetra Tech Canada Inc. and GeoSim Services Inc. to conduct an updated S-K 1300-compliant Mineral Resource Estimate (“MRE”) for the Sarfartoq project in southwest Greenland. Under the agreements, GeoSim will serve as the Qualified Person responsible for the resource estimate, led by Ronald G. Simpson, P.Geo., while Tetra Tech will provide engineering and metallurgical support. Greenland Mines expects the updated MRE to provide the technical foundation for an updated Preliminary Economic Assessment (“PEA”) as well as future engineering studies and public disclosures. 

Updating a Mineral Resource Estimate under SEC Regulation S-K 1300 represents an important milestone for companies listed on U.S. exchanges. The SEC’s Subpart 1300 establishes standardized requirements for reporting mineral resources, mineral reserves and related technical information, providing investors with more consistent and transparent disclosure regarding mining projects. An updated mineral resource estimate also provides the technical foundation for engineering studies, economic evaluations and future project development. 

Greenland Mines noted that the resource estimate will integrate multiple sources of technical information. In addition to incorporating the historic NI 43-101 resource estimates completed in 2011 and 2012, the updated work will include additional drilling, resource modeling and technical studies completed between 2023 and 2025 by Neo Performance Materials and its subsidiary Neo North Star Resources Inc. These studies will transfer to Greenland Mines as part of the company’s acquisition of the Sarfartoq project, creating a more comprehensive technical dataset for evaluating the deposit. 

The company is also continuing to advance the project on several additional fronts. Greenland Mines has initiated the formal process of transferring the Sarfartoq exploration licenses through the appropriate Greenland authorities while simultaneously reappointing WSP Danmark A/S to complete the second year of environmental baseline studies begun under the project’s previous ownership. Together, the updated resource estimate, expanded geological database and ongoing environmental work are intended to support future permitting activities and accelerate the project’s advancement toward updated economic studies.  

One element highlighted by the company is the continuity of technical leadership. Ronald G. Simpson and GeoSim have been involved with Sarfartoq for more than a decade, serving as Qualified Persons for the historic 2011 and 2012 NI 43-101 mineral resource estimates and contributing to the original 2011 Preliminary Economic Assessment. Greenland Mines believes re-engaging many of the technical experts who helped establish the project’s original geological model provides continuity and familiarity with both the resource database and the property’s geology while integrating more recent exploration work.  

According to the company, Sarfartoq is distinguished by its concentration of neodymium and praseodymium, commonly referred to as NdPr. These rare earth elements are essential components in the high-strength permanent magnets used in electric vehicle motors, offshore wind turbines, robotics, industrial automation systems and numerous defense technologies. The U.S. Department of Energy and the International Energy Agency have identified rare earth permanent magnets as among the most strategically important materials supporting the global energy transition and advanced manufacturing. 

The company noted that the historic 2011 Preliminary Economic Assessment evaluated both open-pit and underground mining concepts. Under the current technical program, Tetra Tech will revisit those development alternatives while evaluating additional scenarios, including phased development strategies that could begin with an open-pit operation before transitioning underground. The work also includes updated mine planning, pit optimization, underground optimization studies and revised metallurgical recovery assumptions designed to support a refreshed economic evaluation.  

In addition, Greenland Mines emphasized that Sarfartoq represents one component of a broader corporate strategy rather than a standalone asset. The company is building a portfolio of Greenland mineral projects while exploring downstream processing and industrial partnerships in allied jurisdictions, including Iceland. Management believes combining upstream resource development with potential downstream partnerships could contribute to more resilient supply chains serving North America and Europe. The company’s previously announced transaction structure with Neo Performance Materials, including Neo’s right to purchase up to 60% of Sarfartoq’s Nd-Pr production, further reflects its strategy of supporting a Western-aligned rare earth supply chain.  

As demand for magnet rare earth elements continues to increase across transportation, clean energy, industrial automation and defense applications, projects capable of demonstrating modern technical validation and advancing through the development pipeline are becoming increasingly important. By accelerating work on an updated S-K 1300 mineral resource estimate while expanding its geological, engineering and environmental database, Greenland Mines is positioning the Sarfartoq project for the next phase of technical evaluation as it continues pursuing its broader objective of building a strategically important critical minerals platform in Greenland.

For more information, visit www.GreenlandMines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML